This executive summary of the 2025 WAO Guidelines covers the classification, diagnosis, and management of hereditary angioedema (HAE), including an updated endotype-based framework distinguishing bradykinin-mediated, VEGF-mediated, mast cell-mediated, and idiopathic forms, with guidance on on-demand treatment, short-term prophylaxis, and long-term prophylaxis.
First-line on-demand treatments are C1-INH concentrate (IV), icatibant (SC), and sebetralstat (oral); first-line long-term prophylaxis options include plasma-derived C1-INH (SC), lanadelumab (SC), berotralstat (oral), garadacimab (SC), and donidalorsen (SC), selected via a treat-to-target approach aimed at freedom from attacks and quality-of-life impairment.
This is an executive summary of a guideline — not a primary study — so it does not report original trial data, effect sizes, or patient-level outcomes. Global disparities in access to diagnostics and therapies limit universal applicability of the recommendations.
Suspect HAE in any patient with recurrent angioedema without urticaria, especially with abdominal or airway involvement, early onset, or family history; confirm with C1-INH functional testing. Ensure all HAE patients have access to at least 2 doses of effective on-demand therapy, and individualize long-term prophylaxis using a treat-to-target strategy with regular reassessment.
Explore related topics